MPR Weekly Dose 71 - Guidance for those fully vaccinated; A first in COVID-19 testing; Povidone Iodine and Bamlanivimab-Etesevimab examined; Delayed local vaccine reactions
This week it's all COVID related news; There's new CDC guidance for those who are vaccinated; A first over the counter test that doesn't require a prescription; Nasopharyngeal povidone iodine and the ...
12 Mar 202110min
MPR Weekly Dose 70 - Keytruda indication withdrawn; Janssen's single-shot vaccine gains EUA; Ivermectin assessed for mild COVID-19; FDA clears wearables
This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen's single dose vaccine gains Emergency Authorization; There's findings on the effectiveness of Iverm...
5 Mar 202111min
MPR Weekly Dose #69 - False and misleading pharma promo; Novel LDL-C therapy; Heart failure Tx expanded; Migraine device okay'd for teens.
An FDA warning over pharma company's promo material; Entresto's approval is expanded, There's approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropath...
18 Feb 202111min
MPR Weekly Dose #68 - Remdesivir compounding; Emergency Use Authorizations; Sleep apnea device; New Botox approval
This week's stories include a caution about remdesivir; New and updated Emergency Use Authorizations; And new approvals in sleep apnea and for Botox.
12 Feb 202111min
MPR Weekly Dose #67 - Efficacy data for AstraZeneca, J&J and Novovax vaccines; Approvals in analgesia and influenza.
This week we take a look at the remaining prospective COVID vaccines, that includes AstraZeneca, J&J and Novovax; There's also drug approvals for analgesia and influenza.
5 Feb 202111min
MPR Weekly Dose 66 - The Moderna vaccine's efficacy against new variants; Merck ends development of new vaccines; Antiviral treatment combos show promise; New lupus nephritis treatment
On this week's pod: The Moderna vaccine and what we know about its effectiveness against emerging variants; Merck ends it's development of two vaccines; Two separate treatment combos show promise in r...
28 Jan 202112min
MPR Weekly Dose #65 - Johnson & Johnson's vaccine candidate; Blood donations during pandemic; New Tx for heart failure with reduced ejection fraction; A potential Alzheimer drug; Changes to vinca alkaloid labeling
On this week's MPR pod we take a look at the current status of Johnson & Johnson's COVID-19 vaccine candidate; Considerations in assessing blood donors during the pandemic; A newly approved drug to tr...
22 Jan 202110min
MPR Weekly Dose #64 - Pfizer-BioNTech vaccine efficacy against new variant; Ravulizumab trial halted; Rapid concussion test; Novel chronic kidney disease Tx; NSAID recalled
This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood te...
15 Jan 20219min
